👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

Blade Air Mobility director Reginald Love sells $20,619 in shares

Published 12/17/2024, 04:37 PM
BLDE
-

Reginald Love, a director at Blade Air Mobility, Inc. (NASDAQ:BLDE), recently sold a portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Love sold 5,091 shares of Class A common stock on December 13 at a price of $4.0501 per share, totaling approximately $20,619. The sale comes as BLDE shares have experienced an 8% decline over the past week, despite showing strong momentum with a 31% gain over the past six months. InvestingPro analysis indicates the company maintains a healthy balance sheet, holding more cash than debt.

Following this transaction, Love retains ownership of 100,363 shares in the company. The sale was conducted directly by Love, as indicated in the filing. With a current market capitalization of $317 million and a strong current ratio of 6.32, InvestingPro subscribers can access detailed insider trading patterns and 8 additional key insights about BLDE's financial health and market position.

In other recent news, Blade Air Mobility reported strong financial results for Q3 2024. The urban air mobility platform saw a 27.3% year-over-year increase in flight profit and an impressive adjusted EBITDA of $4.2 million, up from $0.8 million the previous year. These advancements were particularly notable in their passenger and medical segments.

Blade's strategic decisions, such as exiting unprofitable markets and forming a partnership with OrganOx, have been key to its recent success. Despite a sequential decline in medical revenue, the company is optimistic about a rebound in Q4 and projects double-digit growth for 2025.

In terms of financial outlook, Blade anticipates revenue between $240 million and $250 million for 2024, with positive adjusted EBITDA. The company also expects medical revenue to grow in low single digits sequentially in Q4. For 2025, Blade predicts double-digit growth in medical revenue and adjusted EBITDA margins of approximately 15%.

While there were challenges, such as a decline in medical revenue due to lower organ transplant volumes, the company maintains a strong balance sheet with significant cash reserves and no debt. It's clear that Blade's strategic moves and robust financial performance have positioned it well for future growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.